ArticleJournal of the American Heart Association2026
Cardiomyocyte-Specific Smad7 Protects the Pressure-Overloaded Heart, Inhibiting the Transforming Growth Factor-β Receptor 1/Smad2/3 Cascade.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effects of TGF-βs (transforming growth factor-βs) in failing hearts involve cell-specific actions mediated through receptor-regulated Smads or Smad-independent pathways. The inhibitory Smad, Smad7, is a negative feedback regulator that restrains excessive TGF-β/receptor-regulated Smad signaling, while also exerting TGF-β-independent effects. We hypothesized that cardiomyocyte Smad7 upregulation contributes to the pathogenesis of pressure overload-induced heart failure and investigated the mechanisms underlying its actions.
methodsCardiomyocyte-specific Smad7 knockout mice and corresponding Cre+ and Smad7
resultsSmad7 was upregulated in cardiomyocytes and fibroblasts following transverse aortic constriction and in patients with nonischemic cardiomyopathy. Cardiomyocyte-specific Smad7 knockout mice had no baseline abnormalities but developed worse systolic and diastolic dysfunction and increased cardiomyocyte hypertrophy after pressure overload. Cardiomyocyte Smad7 loss did not alter fibrosis after transverse aortic constriction but increased macrophage infiltration. Cardiomyocyte-specific Smad7 knockout hearts showed reduced expression of genes associated with cardiac contraction. Bioinformatic analysis identified TGF-β1, angiotensin, and ERBB2 as candidate upstream regulators mediating the effects of Smad7 loss. In vivo, cardiomyocyte Smad7 inhibited activation of TGF-β receptor 1 (TGFBR1)/Smad2/3 and ERBB2 without affecting TGF-β receptor 2 (TGFBR2) activity. In the absence of Smad7, pressure-overloaded cardiomyocytes exhibited increased TGFBR1/Smad3 activation. In H9c2 cells, endogenous Smad7 restrained TGFBR1/Smad3 activation without affecting TGFBR2 or ERBB2 activity.
conclusionsCardiomyocyte Smad7 protects the pressure-overloaded heart from dysfunction, regulating genes involved in muscle contraction, likely through direct suppression of TGFBR1/Smad3.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.